| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.946275 |
| 003 | CaOODSP |
| 005 | 20250220095455 |
| 006 | m o d f |
| 007 | cr ||||||||||| |
| 008 | 241217e202501 onc o f000 0 eng d |
| 020 | |a9780660749686 |
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
| 043 | |an-cn--- |
| 086 | 1 |aH164-320/2025E-PDF |
| 245 | 00|aGuidance document : |bpatented medicines (notice of compliance) regulations. |
| 250 | |a[2025 edition]. |
| 264 | 1|aOttawa, ON : |bHealth Canada = Santé Canada, |cJanuary 2025. |
| 264 | 4|c©2025 |
| 300 | |a1 online resource (36 pages) |
| 336 | |atext|btxt|2rdacontent |
| 337 | |acomputer|bc|2rdamedia |
| 338 | |aonline resource|bcr|2rdacarrier |
| 500 | |aIssued also in French under title: Ligne directrice : règlement sur les médicaments brevetés (avis de conformité). |
| 500 | |a"Effective date: 2025/01/14."|3"Pub.: 240714." |
| 650 | 0|aPatent medicines|zCanada. |
| 650 | 0|aPharmaceutical policy|zCanada. |
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
| 775 | 08|tLigne directrice : |w(CaOODSP)9.946274 |
| 795 | |tGuidance document : |w(CaOODSP)9.899807 |
| 856 | 40|qPDF|s507 KB|uhttps://publications.gc.ca/collections/collection_2025/sc-hc/H164-320-2025-eng.pdf |
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/patented-medicines/notice-compliance-regulations.html |
| 986 | |a240714 |